Recent discussions highlight the potential of low-dose, low-cost immunotherapies to improve access to cancer treatments in poorer countries.
These therapies could offer a viable alternative for patients who currently face significant barriers to high-tech cancer care.
As the medical community explores these options, there is cautious optimism about their ability to bridge the gap in healthcare disparities.